

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETAR
02 AUG 1

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name The Washington Group, Inc.			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address 1401 K Street, N.W., Suite 400 City Washington, State/Zip (or Country) DC 20005			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name _____ Telephone _____ E-mail (optional) _____			5. Senate ID # _____
7. Client Name <input type="checkbox"/> Self Ranbaxy Pharmaceuticals, Inc.			6. House ID # _____

TYPE OF REPORT 8. Year 2002 Midyear (January 1-June 30) **OR** Year End (July 1-De

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report >> Termination Date _____ 11. No Lobby

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this reporting period were:
Less than \$10,000 <input type="checkbox"/>	Less than \$10,000 <input type="checkbox"/>
\$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$100,000.00</u> Income (nearest \$20,000)	\$10,000 or more <input type="checkbox"/> >> \$ _____ Expenses (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of
	<input type="checkbox"/> Method A. Reporting amounts using LDA definit
	<input type="checkbox"/> Method B. Reporting amounts under section 603 the Internal Revenue Code
	<input type="checkbox"/> Method C. Reporting amounts under section 162 Internal Revenue Code

Signature

John D. Roffelli

Date 7/31/2002

Registrant Name: The Washington Group, Inc.Client Name: Ranbaxy Pharmaceuticals, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code**, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific Lobbying issues

17. House(s) of Congress and Federal agencies contacted

Executive Office of the President
House of Representatives
Senate

 Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Burke, William	
Crane, David	Senior Policy Advisor to Senator Trent Lott
Edwards, Melissa	
Farmer, Kimberley	
Lewis, Rita	
O'Hanlon, G. John	
Raffaelli, John D.	

19. Interest of each foreign entity in the specific issues listed on line 16 above

 Check if None

Signature _____

Date 7/31/2002

Registrant Name: The Washington Group, Inc.Client Name: Ranbaxy Pharmaceuticals, Inc.

Item	Description	Data
18a	Lobbyist Name	Saunders, Tonya
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Schnabel, Mark
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Sporidis, Harry
18b	Covered Official Position	
18c	New Lobbyist	No

Registrant Name: The Washington Group, Inc.Client Name: Ranbaxy Pharmaceuticals, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code**, provide information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (one per page)

16. Specific Lobbying issues

17. House(s) of Congress and Federal agencies contacted
Executive Office of the President
House of Representatives
Senate

 Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Burke, William	
Crane, David	Senior Policy Advisor to Senator Trent Lott
Edwards, Melissa	
Funderburk, Tripp	
Lewis, Rita	
O'Hanlon, G. John	
Raffaelli, John D.	

19. Interest of each foreign entity in the specific issues listed on line 16 above

 Check if None

Signature _____

Date 7/31/2002

Registrant Name: The Washington Group, Inc.Client Name: Ranbaxy Pharmaceuticals, Inc.

Item	Description	Data
18a	Lobbyist Name	Saunders, Tonya
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Schnabel, Mark
18b	Covered Official Position	
18c	New Lobbyist	No

